Gary J. Richmond, MD
Current leadership positions
Clinical Associate Professor, Florida International University, Miami FL
Medical Director, Respiratory Therapy Program, Broward College, Fort Lauderdale, Florida
Clinical Instructor, Broward College, Fort Lauderdale, Florida
Clinical Assistant Professor, NOVA Southeastern College of Osteopathic Medicine
COPD, Interstitial Lung Disease, Pulmonary Hypertension
American Board of Internal Medicine
American Board of Internal Medicine - Pulmonary Disease
Fellow, American College of Chest Physicians
Fellow, American College of Physicians
Internal Medicine: Beth Israel Medical Center, New York, NY
Pulmonary Medicine: University of California, San Francisco
Summa cum Laude, B.S. University of Massachusetts
American Thoracic Society
American College of Chest Physicians
American College of Physicians
Broward County Medical Society
Florida Medical Society
Compassionate Doctor Recognition, MDx Medical
Patients' Choice Award, MDx Medical
Lifetime Service Award, World AIDS Day 2008
Physician’s Recognition Award, American Medical Association
Most Valuable Physician Award, Broward General Medical Center
Phi Beta Kappa Honor Society
Phi Kappa Phi Honor Society
Zoology Departmental Honors, University of Massachusetts
Elion R, deJesus E, Sension M, Berger D, Towner W, Richmond G, St..Clair M, Yau L, Ha B. Once daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study. HIV Clin Tirals 2008;9(3):152-163.
Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Abdominal Fat Accumulation. AIDS. 2008, 22: 1719-1728.
Lalezari J, Yadavalli G, Para M, Richmond G, DeJesus E, Brown S, Cai W, Chen C, Zhong J, Novello L, Lederman M, Subramanian G. Safety, pharmacokinetics and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1 infected patients. Journal of Infectious Diseases 2008; 197:721-727.
Tabas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Chiu Y, Evans C, Rowell L, Salgo M. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of apharmacokinetic study of enfuvirtide in HIV-1 infected patients with impaired kidney function. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2008; 47(3):342-5.
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S. Effects of a Growth Hormone Releasing Factor Analogue on Body Composition and Metabolic Indices in HIV-Infected Patients. New England Journal of Medicine. 2007;357:2359-70.
Thors A, Guarneri R, Costantini G, Richmond G. Atrial Septal Rupture, Flail Tricupsid Valve, and Complete Heart Block Due to Nonpenetrating Chest Trauma. Annals of Thoracic Surgery 2007;83:2207-2210.
Grunfeld C, Thompson M, Brown S, Richmond G, Lee D, Muurahainen N, Kotler D. Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12 Week Induction and 24-Week Maintenance Therapy. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2007;45(3):286-97.
Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu U, Zhang Y, McFalls E, Miralles D, Patel I. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice daily dosing with enfuvirtide in HIV-infected subjects. AIDS 2006, 20:397-404.
Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J. Infect Dis. 191(&): 1155-63, 2005 April 1.
Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Shaefer M. Pharmacodynamic Effects of Zidovudine 600 mg Once/Day Versus 300 mg Twice/Day in Therapy-Naïve Patients Infected with Human Immunodefiency Virus. Pharmacotherapy 24(3):307-312, 2004.
Ruane P, Kubota M, Williams A, Arroyo J, Canas A, Richmond G, Alsop CA, Yau L, Hessenthaler S, Hernandez J. Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1 Infected Adults in a Clinical Practice Setting: Results of ZORRO. Infectious Diseases in Clinical Practice 2004, 12:1, 15-25.
Hornberger, J, DeJesus E, Rockstroh J, Richmond G, Cavassini M, Green J. Clinical prognosis of patients receiving Enfuvirtide (T-20) in combination with an optimized background regimen. Submitted to Journal of AIDS 2003.
Lalezari JP, DeJesus E, Northfelt DW, Richmond GJ, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlosn M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with Abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naïve HIV-infected adults. Antiviral Therapy. 8(4):279-87, 2003 Aug.
Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster T, Hernandez JE, Pappa KA. Twice Daily Amprenavir 1200 mg versus Amprenavir 600 mg / Ritonavir 100 mg in combination with at least 2 other antiretroviral drugs in HIV-1 infected patients. BMC Infectious Diseases 2003:3,10.
Murray FT, Muurahainen N, Gertner JM, Williams A, Santos G, Scheperle M, Richmond G, Findelstein J, Nebiolo L, Gaccione, P. HIV Patient Acceptance of a Needle-Free Device (SeroJet™) for Administering Recombinant Human Growth Hormone in the Treatment of HIV Infection-Associated Cachexia. Journal of New Developments in Clinical Medicine. 2001,19:4, 283-295.
Fogarty C, Cammarata S, Oliphant T, Richmond G. Linezolid versus Cefpodoxime in the Outpatient management of Community Acquired Pneumonia, A Randomized, Investigator-Blind Comparison. Submitted for publication. Annals Internal Medicine. 2000.
Jacques C, Richmond G, Tierney L, Curtis J, McKerrow J, Warnock M. Primary Pulmonary Hypertension and HIV Infection in a Non-Hemophiliac Man. Human Pathology 1992, 23:191-194.
Richmond G, Handweger S, Schoenfeld N, Talavera W. Superior venal caval syndrome: A Complication of Hickman Catheter Insertion in Patients with AIDS. New York State J. of Medicine. 1992, 92:2;65-66.
Ovary Z, Itaya T, Santomauro J, Richmond G. On the Stability of IgE Antibodies. J. Immunol. Methods. 1978, 24:193-194.
Soriano V, Cox J, Eron J, Kumar P, Katlama C, Lazzarin A, Poizot-Martin I, Richmond G, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J. Dolutegravir (DTG, S/GSK1349572) treatment of HIV subjects with raltegravir resistance: viral suppression at Week 24 in the VIKING study. 13th European AIDS Conference, October 2011, Belgrade Serbia.
Cloete B, Katlama C, Soriano V, Lazzarin A, Richmond G, Huang J, Vavro CL, Underwood MR, Ait-Khaled M, Nichols, W. HIV Integrase Resistance and Phenotypic Susceptibility to Dolutegravir (DTG, S/GSK1349572) for Subjects with Virologic Failure on Raltegravir (RAL). 9th European Workshop on HIV and Hepatitis, March 25, 2011, Paphos, Cyprus.
Eron J, Kumar, P, Lazzarin A, Richmond G, Soriano V, Huang J, Vavro C, Ait-Khaled M, Min S, Yeo J. Dolutegravir (DTG, S/GSK1349572) in Subjects with HIV Exhibiting Raltegravir (RAL) Resistance: Functional Monotherapy Results of VIKING Study Cohort II. Abstract L-1005. 18th Conference on Retroviruses and Opportunistic Infections, February 2011.
Eron J, Durant J, Poizot-Martin I, Reynes J, Soriano V, Kumar P, Richmond G, Vittecoq D, Fujiwara T, Ait-Khaled M, Mins, Thomas D, Cuffe R, Yeo J. Activity of Next Generation Integrase Inhibitor (INI)S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961). XVIII International AIDS Conference, July 2010, Vienna, Austria.
Arribas J, Lazzarin A, Raffi F, Rakhmanova A, Richmond G, Rockstroh J, van Lunzen J, Young B, Almond S, Brothers C, Min S, Nichols G. Once Daily S/GSK1379572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276). XVIII International AIDS Conference, July 2010, Vienna, Austria.
Elion R, Berger D, Richmond G, Sension M, deJesus E, Cimoch P, St. Clair M, Ha B. Simplified Maintenance Therapy with Abacavir/Lamivudine and Atazanavir After Discontinuation of Ritonavir. HIV Clinical Trials. Submitted for publication. 2010.
Lalezari J, Richmond G, Thompson M, Cohen C, Fidler M, Balch A, Beelen A. Pharmacokinetics and Safety of Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV Infection. 49th ICAAC September 2009.
Min S, DeJesus E, McCurdy L, Richmond G, Torres J, Ford S, Chen S, Lou Y, Bomar M, Cyr T, St. Clair M, Fujiwara T, Piscitelli S. Pharmacokinetics and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor. 49th ICAAC Sept 2009, Oral Presentation.
Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, Richmond G, Thompson M, Martin D. A Phase II Safety and Efficacy Study of Bevirimat (BMV) in Heavily Treatment Experienced HIV+ Patients Identifies the Target Phase III Study Profile. ICAAC/ISDA October 2008, A-954 and oral presentation.
McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, Salzwedel K, Allaway G. HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-456). Sitges Resistance Workshop April 2008.
Falutz J, Allas S, Mamputu JC, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S. Data on 52-Week Safety and Efficacy of Tesamorelin (TH9507), a Growth Hormone Releasing Factor Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation. 15th Conference on Retroviruses and Opportunistic Infections. 2008; Poster 943.
Elion R, Berger D, Richmond G, Sension M, DeJesus E, Cimoch P, Yau L, Ha B. Simplified maintenance therapy with ABC/3TC + ATC after ABC/3TC + ATV/RTV Induction for 48 weeks. Conference of American College of Clinical Pharmacy, Oct 2008. Poster 97.
Richmond G, Kotler D, Freedland E. Relationship between baseline visceral adipose tissue (VAT) and VAT loss during reatment with recombinant human growth hormone (r-hhGH) in patients with human immunodeficiency virus infection-associated adipose redistribution syndrome (HARS). Poster 887, Infectious Disease Society of America Annual Meeting Oct 2007.
Kotler D, Richmond G, Bassinger S, Freedland E. 36 weeks of treatment with recombinant human growth hormone improves anthropometric parameters in patients with HIV Adipose Redistribution Syndrome (HARS). US Conference on AIDS, Nov 2007.
DeJesus E, Sension M, Berger D, Towner W, Richmond G, Yau L, Ha B. Once Daily Abacavir/Lamivudine and Boosted Atazanavir: 48 Week Analysis from COL102060 (SHARE). 4th International AIDS society Conference on HIV Pathogenesis, July 2007.
Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Buss N, Chiu Y-Y, Powell L, Salgo M. Enfuvirtide Does Not Require Dose-Adjustment in Patients with Chronic Renal Failure: The Results of a Pharmacokinetic Study of Enfuviride in HIV-1-Infected Patients with Impaired Renal Function. 14th Conference on Retroviruses and Opportunistic Infections, Feb. 2007
Falutz J, Allas S, Blot K, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S. Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients. 14th Conference on Retroviruses and Opportunistic Infections, Oral Abstracts, Feb. 2007.
Lalezari J, Lederman M, Yadavalli G, Para M, Richmond G, DeJesus E, Searle J, Cai W, Roschke V, Zhong J, Hicks C, Friemuth W, Subramanian M. A Phase I, randomized, dose-escalation, placebo controlled study of a fully human monoclonal antibody against CCR5 (HGS004) in patients with CCR5 tropic HIV-1 infection. Oral Presentation. 46th ICAAC San Francisco September 2006.
Turner RR, Testa MA, Su M, Richmond GJ, Muurahainen N, Kotler DP, Thompson M. The Impact of HIV-Associated Adipose Redistribution Syndrome (HARS) on Health-Related Quality of Life. Submitted to 2006 ICAAC.
Grunfeld C, Brown S, Richmond G, Muurahainen N, Kotler D. Cardiovascular risk factors in patients with HIV-Associated Adipose Redistribution Syndrome (HARS). 7th Internationsal Workshop on Adverse Drug Reactions and Lipodystrophy. Dublin, Ireland. November 15, 2005. Poster 32.
Cohen C, Murphy R, Katlama C, Gathe J, Brinson C, Richmond G, Girard P, Fessel J, Liappis A. Efficacy and Tolerability of once daily doses of Reverset, a cytidine analog NRIT, in ARV-experienced patients. LB-1. International AIDS Society Meeting 2005, Buenos Ares, Argentina.
Dushyantha J, Sathasasivam K, Richmond G, et.al. A Once Daily Efavirenz Based Regimen for Treatment Naïve HIV Subjects: 96 Week Results from the DART II Trial. 092-800. Infectious Diseases Society of America (ISDA) October 8, 2005
Lalezari JP, Bellos N, Richmond G, Sathasivam K, Cohen C, Myers R, Henry D, Raskino C, Zhang Y, Spence B, Demasi R, Miralles D. Final analysis of T1249-102: T-1249 retains short term antiviral activity in patients who have failed a regimen containing enfuvirtide. H-444. 43rd ICAAC September 2003, Chicago IL.
Muurahainen N, Richmond G, Williams B, Witek J, Henry K, Oldfield E, Cure-Bolt N, Oliver C. Effect of r-hGH on Viral Load of Patients with HIV-associated Weight Loss on Highly Active Antiretroviral Therapy. H-1920. 43rd ICAAC September 2003, Chicago IL.
Chiu YL, Foit C, Gathe J, Podzamezer D, Johnson M, Clotet B, Cimoch P, Pozniak A, Richmond G, Schneider S, Arribas J, King M, Marsh T, Naylor C, Tressler R, Bertz R. Multiple-Dose Pharmacokinetics and Initial Antiviral Effect of Once Daily Lopinavir/Ritonavir in Combination with Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects. IAS Conference on HIV Pathogenesis, Paris France July 2003.
Thompson, M, Richmond, G, Kessler, H, Bae A, Sorbel J, Sista N, Adda N and Rousseau F. Preliminary Results of Dosing of Amdoxovir in Treatment-Experienced Patients. 10th Conference on Retroviruses and Opportunistic Infections, Boston MA February 2003.
Miralles GD, Lalezari PH, Bellos N, Richmond G, Zhang Y, Murchison H, Spense R, Raskino C, Demasi RA. T-1249 Demonstrates Potent Antiviral Activity over 10 Day Dosing in Most Patients who Have Failed a Regimen Containing Enfuvirtide (ENF): Planned Interim Analysis of T1249-102, a Phase I/II Study. 10th Conference on Retroviruses and Opportunistic Infections, Boston MA February 2003.
Lalezari J, DeJesus E, Northfelt D, Richmond G, Delehanty J, Demasi R, Salgo M. A Week 48 Assessment of a Randomized, Controlled, Open-Label Phase II Trial (T20-206) Evaluating Three Doses of T-20 in PI-Experienced, NNRTI-Naïve Patients Infected with HIV-1. 9th Conference on Retroviruses and Opportunistic Infections, Seattle WA February 2002. #418-W
Nadler J, Gathe J, Pollard R, Richmond G, Liao Q, Lancaster T, Griffith S, Pappa K, Hernandez J. Efficacy and Safety of APV/RTV 600/100 mg BID Compared to APV 1200 mg BID in ART experienced and naïve subjects: ESS40011. 14th International AIDS Conference, Barcelona, Spain August 2002. #TUPEB4463.
Ruane P, Hernandez J, Richmond G, Williams A, Fralich T, Yau L, Hessenthaler S, Lanier ER. Geotypic (GT) and Virtual Phenotypic (vPT) Correlates of Virologic Response to Abacavir (ABC)-based Therapy in the ZORRO Trial (ESS40009).14th International AIDS Conference, Barcelona, Spain August 2002. #ThOrB1386.
Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Schaeefer M. Pharmacodynamic effects of zidovudine 600 mg once daily versus zidovudine 300 mg twice daily in therapy-naïve HIV-infected patients (COD20002). 14th International AIDS Conference, Barcelona, Spain August 2002. #LBPEB9020.
Richmond G, Appleby V, Strawbridge T. The Use of Recombinant Human Growth Hormone for Dorsocervical Fat Pad Accumulation in a Patient on Highly Active Antiretroviral Therapy. Fourteenth Annual Conference Association of Nurses in AIDS Care, Minneapolis, MN, November 2001
Richmond G, Nebiolo L, Rosen A, Finkelstein J, Landy H, Muurahainen. Safety and Efficacy of Recombinant Human Growth Hormone Serostim® for HIV Associated Wasting in the Era of Highly Active Antiretroviral Therapy. Fourth International Conference on Nutrition and HIV Infection, Cannes, France April 2001.
Richmond G and the Testoderm Study Group. A Multicenter Clinical Trial Evaluation Physiologic Replacement of Testosterone in Hypogonadal Men with AIDS-Related Weight Loss. Submitted to 4th Conference on Retroviruses and Opportunistic Infections, October 1996.
Richmond G, Zolnouni P, Stall J, McPherson M, Hamedani P, Cross V, et.al. Efficacy and Safety of MDL 28,574A in HIV-Positive Patients with Baseline CD4 Values of 301-500. XI International Conference on AIDS, Vancouver Canada, July 1996.
Richmond G, Appleby V. Home Infusion Therapy in the Management of HIV Disease using the PAS-Port™ Catheter. III Osterreichischen AIDS-Kongress. Vienna, Austria. September 1992.
Richmond G, Imoto E, Doherty J, Beck J, Brown J. Prophylaxis with Inhaled Pentamidine does not Diminish the Yield of Sputum Induction for Diagnosis of Pneumocystis Carinii Pneumonia. 1991 International Conference of the American Thoracic Society and American Lung Association. American Review of Respiratory Diseases: 1991, 143,4:A716.